Grants / Department of Health and Human Services / National Institutes of Health

RFA-NS-21-029: HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)

Closed Closed October 10, 2023 Opportunity RFA-NS-21-029 ☆ Save

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.

• Award amountsNot given on Grants.gov
• Cost sharingNot required
• Funding typeGrant

Key dates

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

• Most of the money in the 9 programs behind this notice (73% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

Reissue of RFA-NS-21-016: The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R61 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R61 awards will support the building of a research team to collect initial data and recruit additional collaborators. The proposal must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.

Category: Health, Income Security and Social Services.

Other programs behind this notice

• Child Health and Human Development Extramural Research 93.865
  $6.0 billion in five years
• Vision Research 93.867
  $3.4 billion in five years
• Arthritis, Musculoskeletal and Skin Diseases Research 93.846
  $2.6 billion in five years
• Alcohol Research Programs 93.273
  $2.2 billion in five years
• Oral Diseases and Disorders Research 93.121
  $1.9 billion in five years
• Research and Training in Complementary and Integrative Health 93.213
  $575 million in five years

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.